Tissue genotyping of 37 in situ and invasive cervical cancer with a concomitant negative HC2 HPV DNA Test

Journal of Lower Genital Tract Disease

Volumn 18, Issue 1, 2014, Pages 87-91

  Igidbashian, Sarah ^a   Schettino, Maria Teresa ^b   Boveri, Sara ^a   Barberis, Massimo ^c   Sandri, Maria Teresa ^a   Carinelli, Silvestro ^c   Cannone, Maria ^d   Sideri, Mario ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Histopathologic and Molecular Diagnosis Unit   (Italy)

^d IRCCS MULTIMEDICA   (Italy)

Author keywords

cervical cancer; CIN 3; high risk HPV; HPV negative CIN 3+

Indexed keywords

ADULT; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HISTOCYTOCHEMISTRY; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84894102488     PISSN: 10892591     EISSN: 15260976     Source Type: Journal    
DOI: 10.1097/LGT.0b013e3182909f86     Document Type: Article

References (19)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
2. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24S3:S1-10.
3. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: A metaanalysis. Br J Cancer 2003; 88:63-73.
4. Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: Implications for screening and prevention. J Natl Cancer Inst 2006;98:303-15.
5. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
6. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-64.
7. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses. Vaccine 2006;24:S78-89.
8. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al; Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357:1579-88.
9. Naucler P, Ryd W, To rnberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009;101:88-99.
10. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al; New Technologies for Cervical Cancer Screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: A randomised controlled trial. Lancet Oncol 2010;11:249-57.
11. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: Final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012;13:78-88.
12. Dillner J, ReboljM, Birembaut P, Petry KU, Szarewski A, Munk C, et al; Joint European Cohort Study. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: Joint European Cohort Study. BMJ 2008;337:a1754.
13. Lorincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 2003;127:959-68.
14. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009;124:516-20.
15. Castle PE, Cox JT, Jeronimo J, Solomon D, Wheeler CM, Gravitt PE, et al. An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUSLSIL Triage Study (ALTS). Obstet Gynecol 2008;111:847-56.
16. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: A population-based study in routine clinical practice. Lancet Oncol 2011;12:663-72.
17. Sandri MT, Riggio D, Salvatici M, Passerini R, Zorzino L, Boveri S, et al. Typing of human papillomavirus in women with cervical lesions: Prevalence and distribution of different genotypes. J Med Virol 2009;81:271-7.
18. Sideri M, Cristoforoni P, Casadio C, Boveri S, Igidbashian S, Schmitt M, et al. Distribution of human papillomavirus genotypes in invasive cervical cancer in Italy: A representative, single institution case series. Vaccine 2009; 27:A30-3.
19. Carozzi FM, Tornesello ML, Burroni E, Loquercio G, Carillo G, Angeloni C, et al; HPV Prevalence Italian Working Group. Prevalence of human papillomavirus types in highgrade cervical intraepithelial neoplasia and cancer in Italy. Cancer Epidemiol Biomarkers Prev 2010;19:2389-400.